Skip to main content

Adaptimmune Therapeutics PLC

ADAPY
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001621227

No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Adaptimmune Therapeutics PLC insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Adaptimmune Therapeutics PLC, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Adaptimmune Therapeutics PLC
NameTitleLast reported holdingLast filingFilings, past year
Wood GavinChief Financial Officer0Sep 3, 20250
Bertrand William C JRChief Operating Officer986,352Aug 29, 20250
Behbahani AliDirector0IndirectAug 19, 20250
EcoR1 Capital, LLC10% Owner100,371,882IndirectJul 30, 20250
Rawcliffe AdrianChief Executive Officer44,327Feb 20, 20250
Lunger JohnChief Patient Supply Officer7,510Feb 20, 20250
Norry ElliotChief Medical Officer7,510Feb 20, 20250
Piccina CintiaChief Commercial Officer18,421Feb 20, 20250
Brewer Joanna ElizabethChief Scientific Officer–Feb 20, 20250
Mott David MDirector–Jul 1, 20240
Hege KristenDirector–Jul 1, 20240
Allen Andrew RDirector–Jul 1, 20240
Alleva Lawrence MDirector–Jul 1, 20240
Menzel Garry EDirector75,056Jul 1, 20240
Furey JohnDirector–Jul 1, 20240
Hegde PritiDirector–Jul 1, 20240
Tayton-Martin Helen KatrinaChief Business & Strgy Officer–Jan 17, 20240
Sigal Charles ElliottDirector–Jul 3, 20230
Duncan Barbara GayleDirector–Jul 1, 20220
Noble JamesDirector–Jul 1, 20220
Zaks Tal ZviDirector–Jul 1, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jan 15, 2025 (view filing)Jan 13-152 daysNorry ElliotChief Medical OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−22.2K$0.5812−$12.9K−61.7%13.8K after3 lots
Jan 15, 2025 (view filing)Jan 15Same dayPiccina CintiaChief Commercial OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−13.0K$0.57−$7.40K−41.4%18.4K after
Jan 15, 2025 (view filing)Jan 13-152 daysRawcliffe AdrianChief Executive OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−59.6K$0.5802−$34.6K−58.9%41.6K after3 lots
Jan 17, 2025 (view filing)Jan 17Same dayRawcliffe AdrianChief Executive OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−30.6K$0.58−$17.7K−40.8%44.3K after
Jan 17, 2025 (view filing)Jan 17Same dayBertrand William C JRChief Operating OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−5.58K$0.58−$3.24K−42.6%7.51K after
Jan 17, 2025 (view filing)Jan 17Same dayLunger JohnChief Patient Supply OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−5.58K$0.58−$3.24K−42.6%7.51K after
Jan 17, 2025 (view filing)Jan 17Same dayNorry ElliotChief Medical OfficerSSaleAmerican Depositary Shares representing Ordinary Shares−5.58K$0.58−$3.24K−42.6%7.51K after
Jul 30, 2025 (view filing)6:20 PM ETJul 28-302 daysEcoR1 Capital, LLC10% OwnerSSale−64.1M$0.1076−$6.89M−39.0%100.4M after3 lotsPrice outlier
Aug 19, 2025 (view filing)7:07 PM ETAug 15-184 daysBehbahani AliDirectorSSaleOrdinary Shares with a nominal value of 0.001 GBP per share−19.5M$0.0118−$229.2K−100.0%0 after2 lots
Aug 29, 2025 (view filing)6:25 PM ETAug 281 dayBertrand William C JRChief Operating OfficerSSaleOrdinary Shares with a nominal value of GBP0.001 per share−207.0K$0.0101−$2.09K−17.3%986.4K after
Sep 3, 2025 (view filing)5:00 PM ETSep 21 dayWood GavinChief Financial OfficerSSaleOrdinary Shares with a nominal value of GBP0.001 per share−96.0K$0.0099−$950.4−100.0%0 after